|
|
 |
|
Viewing report
|
|
|
|
Forecast Insight: Antidiabetics - Diabetes Market Growth Driven by Epidemiological Trends and Rich Pipeline
Datamonitor, Sep 2010, Pages: 125
The antidiabetics market is expected to grow to $34.8 billion in 2019 for the seven major markets. Januvia will become the leading franchise from 2012 after patent expiry of Actos, with franchise sales reaching nearly $6 billion by 2019. Pipeline candidates will make up 30% of sales in 2019, with once-weekly GLP-1 agonists and new long-acting insulin analogs meeting success.
Scope
- Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview
- Event-driven updated sales forecasts for 2010-19 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan
- Analysis of major events and brand dynamics affecting the diabetes market
- Understand the barriers to uptake for novel antidiabetics agents and quantify the shift away from older therapies like glitazones and sulfonylureas
Highlights
The antidiabetics market in the seven major markets is expected to grow from $22,806 million in 2009 to $34,820 million in 2019, with a 4% CAGR. Growth is driven by the epidemiological expansion of the market, fuelled by the obesity epidemic and improved diagnosis rates.
Januvia will be the leading oral antidiabetic agent after the patent expiry of Actos. Its relatively benign safety profile has led to rapid growth since launching in 2006, despite a poorer efficacy than other oral antidiabetics. Marketed and pipeline class competitors are seen as 'me-too' drugs and will struggle to attract share away from Januvia.
New products launched from the highly active antidiabetic pipeline will command 30% ($10,570m) of the market in 2019. Highest growth will be seen for the GLP-1 agonists, with the first once-weekly product, Bydureon, expected to take share from within the class, insulins and oral antidiabetics.
Reasons to Purchase
- Quantify the future size of the antidiabetics market from 2010-2019 and identify opportunities for new products
- Examine the future performance of leading antidiabetic brands and the growth of generics and insulin biosimilars
- Understand the barriers to uptake for novel antidiabetic agents
Customers who bought this item also bought
Pipeline Insight: Insulin Antidiabetics - Novel analogs show promise as alternative delivery methods prove less attractive.
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
Antidiabetics Market Forecast
European Diabetes Therapeutics Market
Commercial Insight: Cardiovascular and Metabolic Market Forecast
Indian Diabetes Market Report & Outlook For 2010-2015
Saudi Arabia Diabetes Market Report & Forecast 2011-2016
The Diabetes Market Outlook to 2016
France Diabetes Market Forecast 2011-2016
|
|
|
|
